No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The NMDA Receptor 2B Antagonist market is a subset of the Central Nervous System Drugs market. It is composed of drugs that target the NMDA receptor 2B subtype, which is involved in a variety of neurological processes. These drugs are used to treat a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. They are also used to treat depression, anxiety, and other psychiatric disorders.
NMDA Receptor 2B Antagonist drugs are typically administered orally or intravenously. They are often used in combination with other drugs to maximize their effectiveness. Common side effects of these drugs include dizziness, headache, nausea, and fatigue.
Several companies are involved in the NMDA Receptor 2B Antagonist market. These include AstraZeneca, Eli Lilly, Merck, Pfizer, and Novartis. Show Less Read more
